Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

285 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Villaruz LC, Socinski MA, Abberbock S, Berry LD, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Varella-Garcia M, Franklin WA, Camidge DR, Sequist LV, Haura EB, Ladanyi M, Kurland BF, Kugler K, Minna JD, Bunn PA, Kris MG. Villaruz LC, et al. Among authors: sequist lv. Cancer. 2015 Feb 1;121(3):448-56. doi: 10.1002/cncr.29042. Epub 2014 Oct 1. Cancer. 2015. PMID: 25273224 Free PMC article.
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jänne PA. Jackman DM, et al. Among authors: sequist lv. Clin Cancer Res. 2006 Jul 1;12(13):3908-14. doi: 10.1158/1078-0432.CCR-06-0462. Clin Cancer Res. 2006. PMID: 16818686
Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents.
Lynch TJ, Adjei AA, Bunn PA Jr, Eisen TG, Engelman J, Goss GD, Haber DA, Heymach JV, Jänne PA, Johnson BE, Johnson DH, Lilenbaum RC, Meyerson M, Sandler AB, Sequist LV, Settleman J, Wong KK, Hart CS. Lynch TJ, et al. Among authors: sequist lv. Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4365s-4371s. doi: 10.1158/1078-0432.CCR-06-1005. Clin Cancer Res. 2006. PMID: 16857812 No abstract available.
Epidermal growth factor receptor mutation testing in the care of lung cancer patients.
Sequist LV, Joshi VA, Jänne PA, Bell DW, Fidias P, Lindeman NI, Louis DN, Lee JC, Mark EJ, Longtine J, Verlander P, Kucherlapati R, Meyerson M, Haber DA, Johnson BE, Lynch TJ. Sequist LV, et al. Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4403s-4408s. doi: 10.1158/1078-0432.CCR-06-0099. Clin Cancer Res. 2006. PMID: 16857818 Review.
Novel agents in the treatment of lung cancer: Fourth Cambridge Conference.
Lynch TJ, Bonomi PD, Butts C, Davies AM, Engelman J, Govindan R, Herbst RS, Heymach JV, Johnson BE, Martins RG, Perez-Soler R, Riely GJ, Sandler AB, Sequist LV, Socinski MA, Wong KK, Hart CS. Lynch TJ, et al. Among authors: sequist lv. Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4583-8. doi: 10.1158/1078-0432.CCR-07-0716. Clin Cancer Res. 2007. PMID: 17671145
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ. Sequist LV, et al. J Clin Oncol. 2008 May 20;26(15):2442-9. doi: 10.1200/JCO.2007.14.8494. Epub 2008 May 5. J Clin Oncol. 2008. PMID: 18458038 Clinical Trial.
285 results